$41 million boost to fight cancer
Australia’s position as an international leader in cancer research has been strengthened with a $41 million boost to expand research to fight cancer.
The NSW and Commonwealth Governments joined forces today to announce the funding to help researchers apply cutting-edge science to detect, diagnose and treat cancers.
The joint investment will support a world-first proteomics project, ProCan, at the Westmead Children’s Medical Research Institute (CMRI).
The project is analysing and measuring thousands of proteins simultaneously in cancers, and using advanced techniques to learn how to predict the most effective treatments for individual cancers.
Premier Gladys Berejiklian said the NSW Government is investing $21 million in the project.
“The NSW Government is proud to support the CMRI and the ProCan project that will support the work to ultimately crack the cancer code.”
“This will also boost NSW’s international competitiveness and reputation for being at the forefront of research and innovation,” she said.
“Our strong economic management means the NSW Liberals & Nationals have the resources to invest further in medical research and innovation.”
Federal Health Minister Greg Hunt said the Commonwealth Government is contributing $20 million to enhance Australia’s international reputation as a cancer research leader.
“This will support ProCan to create an unprecedented database containing massive amounts of molecular information on all types of cancer,” Mr Hunt said.
“This will have direct benefit for patients and significant potential economic benefits for NSW and Australia.”
NSW Health Minister Brad Hazzard said the combined investment would allow the CMRI to make ProCan a truly global and revolutionary project.
“The concept behind ProCan is to make Westmead the home of the world’s first database of the entire cancer spectrum,” Mr Hazzard said.
The technology will generate results within five to seven years, which will help develop a new method of cancer diagnosis and treatment planning that can give clinicians guidance within 36 hours. It will be particularly powerful for rare cancers.